Taken together, these findings suggest that relatively short prenatal treatment with SMN-restoring therapeutics during critical time periods of brain development is likely to be sufficient to ameliorate neurodevelopmental aspects of SMA. Here, SMN1 is linked to proximal spinal muscular atrophy.